| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
140 |
| Revenues (TTM) (Millions $) |
247 |
| Net Income (TTM) (Millions $) |
-139 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
5 |
Business Description
Valneva SE is a biotech company that specializes in the development, manufacture and commercialization of vaccines for infectious diseases, mainly in the fields of travel and endemic diseases.
It was founded in 2013 and is headquartered in Saint-Herblain, France.
Valneva SE is engaged in the development of a vaccine against Lyme disease, known as VLA15, which is currently in Phase 2 clinical trials.
VLA15 targets six different serotypes of Lyme disease and aims to provide protection against the disease in both adults and children.
The company is also working on a vaccine to prevent chikungunya, a mosquito-borne viral infection that causes debilitating joint pain and fever.
Valneva SE has a strong vaccine manufacturing capability with two facilities, one in Nantes, France, and the other in Livingston, Scotland.
The company has a broad portfolio of commercialized products, including vaccines against Japanese encephalitis, cholera, and typhoid fever.
Valneva SE has a strong focus on innovation and collaboration.
The company partners with leading academic institutions, biotech and pharmaceutical companies, and non-governmental organizations (NGOs) to accelerate the development and commercialization of its vaccines.
Overall, Valneva SE is a leading biotech company in the field of vaccine development, focusing on the prevention of infectious diseases through innovative research and development, efficient manufacturing, and strategic partnerships.
Company Address: Îlot Saint-Joseph, Bureaux Convergence, Bât. A, 12 ter Quai Perrache Lyon 69002
Company Phone Number: 28 07 37 10 Stock Exchange / Ticker: NASDAQ VALN
|
5.13% 
56.35 %